Curb for HCQ and Ivermectin to Treat COVID-19 Patients

Finally, they call it a day for the COVID-19 drugs, HCQ, and ivermectin. The National Taskforce under the control of the Indian Council of Medical Research, ICMR, New Delhi, has made its recent announcements to curtail the use of the drugs, HCQ, and ivermectin to treat the COVID-19 patients.

The directions were presented as revised guidelines to manage the COVID-19 adult patients. Also, it is recommended in the national task force guidelines that the usage of Remdesivir and the usage of Tocilizumab drugs are permitted to treat the COVID-19 patients in specific situations.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

‘Remdesivir is recommended still for treating COVID-19 patients while curtailing the use of HCQ and ivermectin.’

Tweet it Now

It is to be noted that the World Health Organization - WHO, The Food and Drug Administration, FDA- the USA, and The New England Journal of Medicine, NEJM, have already made way earlier recommendations to drop the usage of the HCQ and ivermectin drugs in COVID-19 patients.

Ivermectin overdose

There is a lot of misinformation out there, and you might have heard that taking huge doses of ivermectin is okay. It's not acceptable. Ivermectin levels authorized for human usage can be interacting with other drugs, such as blood thinners. Ivermectin overdose can result in lowering the blood pressure, seizures, vomiting, loose stools, inflammations, coma, and sometimes, in death.

Algae Help Fight Coronavirus
New study maps algae’s antiviral potential along infection pathway, finds promise at every step.

Meanwhile, the national task force of ICMR guidelines also emphasize people in using masks, maintaining hand hygiene, social distancing, and taking antipyretic and multivitamins in case of experiencing any COVID-19 symptoms. It is also advised to seek the advice of the healthcare experts immediately, especially in case of facing breathing issues, persisting fever, or incessant coughing for more than five days.

“HCQ may be considered for removal from the guideline, with a recommendation to use with caution only in clinical trial setting (since there is some genuine uncertainty regarding the possible benefit for severe cases and in low dose). Many studies showing increased mortality risk (10/13) and low mortality benefit of HCQ (2/13). Considering evidence for increased ADE (6/13), especially with azithromycin and only one study showed no increase in ADE (1/13),” said the revised guidelines for Covid management.

COVID-19 in India: 30,773 New Coronavirus Cases, 309 Deaths
In India in the last 24 hours, 30,773 new Covid-19 cases and 309 deaths have been recorded. With the new fatalities, the country's cumulative death toll increased to 4,44,838.

Source-Medindia

Bat-related Coronaviruses More Frequent Than Thought, Says Study
The emerging diseases caused by coronaviruses of bat origin have disrupted global health and economies for two decades, says study.